发明授权
- 专利标题： GIP and exendin hybrid polypeptides
- 专利标题（中）： GIP和毒蜥外泌肽杂合多肽
-
申请号： US13591677申请日： 2012-08-22
-
公开(公告)号： US08895498B2公开(公告)日： 2014-11-25
- 发明人: Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
- 申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
- 申请人地址： US DE Wilmington US CA San Diego
- 专利权人： AstraZeneca Pharmaceuticals, LP,Amylin Pharmaceuticals, LLC
- 当前专利权人： AstraZeneca Pharmaceuticals, LP,Amylin Pharmaceuticals, LLC
- 当前专利权人地址： US DE Wilmington US CA San Diego
- 代理机构： Kilpatrick Townsend & Stockton LLP
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61P3/10 ; C07K7/06 ; C07K14/575
摘要：
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
公开/授权文献
信息查询
IPC分类:
